NDATOPICALGEL
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONDYLOX (podofilox) is a topical gel treatment for anogenital warts that works by inducing necrosis of visible wart tissue through an incompletely understood mechanism. It is a small-molecule product indicated for mucous membrane warts and represents a mature, well-established therapy in dermatology.
$0.017BPart D
LOE ApproachingStable
Product is in late-stage lifecycle with minimal market spending, indicating a small, stable team focused on maintenance and generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CONDYLOX offers limited career growth due to zero linked jobs, minimal spending, and approaching LOE, making it a maintenance-focused role suitable for early-career professionals or those transitioning to generic/post-LOE management. The role emphasizes cost control and market share defense rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on CONDYLOX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.